An international team of researchers has now found a possible active substance against the virus in the naturally occurring substance silvestrol. The substance inhibited the replication of pathogens both in cell culture and ...
Aug 01, 2018
0
0
In a viral haemorrhagic disease where up to 40% of people developing it die, it is remarkable that doctors still do not agree whether the only recognised treatment, an antiviral drug called ribavirin, makes a difference. ...
Jun 05, 2018
1
1
(HealthDay)—There is a probable interaction between paritaprevir/ritonavir/ombitasvir+dasabuvir (PrOD) plus ribavirin with warfarin, according to a case report published online Nov. 3 in the Journal of Clinical Pharmacy ...
Nov 08, 2016
0
0
Data presented today demonstrates that generic direct-acting antivirals (DAAs) are as effective and safe as branded treatments to cure Hepatitis C.
Apr 16, 2016
0
1
A new combination treatment for hepatitis C has potential for patients who were not cured by current treatment options.
Apr 14, 2016
0
1
Findings presented today from a Phase 3 head-to-head study that compared two direct-acting antiviral treatment regimens, demonstrated that the all-oral, once daily combination of elbasvir and grazoprevir was more effective ...
Apr 14, 2016
0
10
(HealthDay)—One of the new, highly effective drugs for treating hepatitis C can cause bradyarrhythmia in some patients, according to a research letter published in the Nov. 5 issue of the New England Journal of Medicine.
Nov 05, 2015
0
5
Favipiravir, an investigational antiviral drug currently being tested in West Africa as a treatment for Ebola virus disease, effectively treated Lassa virus infection in guinea pigs, according to a new study from National ...
Oct 13, 2015
0
4
(HealthDay)—Technivie (ombitasvir, paritaprevir and ritonavir) has been approved by the U.S. Food and Drug Administration, in tandem with ribavirin, to treat hepatitis C genotype 4 infection among people without cirrhosis ...
Jul 25, 2015
0
21
Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These ...
Apr 25, 2015
0
6
